EA
FENC icon

Eudaimonia Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Eudaimonia Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$393K Buy
35,359
+2,673
+8% +$26.8K 0.21% 118
2023
Q4 		$367K Buy
32,686
+15,556
+91% +$129K 0.24% 112
2023
Q3 		$129K Hold
17,130
– – 0.09% 141
2023
Q2 		$151K Buy
+17,130
New +$142K 0.1% 145

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Eudaimonia Advisors's FENC Position: Q1 2024 in Review

Eudaimonia Advisors increased its Fennec Pharmaceuticals (FENC) stake by 8.2% in Q1 2024, buying an estimated $26.8K and bringing the position to 35,359 shares worth $393K. The position accounts for 0.21% of the portfolio, ranked #118.

Eudaimonia Advisors first reported a position in FENC in Q2 2023 and has held it in 4 quarters since. 65 funds tracked by Wall St. Rank hold FENC as of Q1 2024.

  • Eudaimonia Advisors held 35,359 shares of Fennec Pharmaceuticals worth $393K as of Q1 2024.
  • Eudaimonia Advisors bought 2,673 Fennec Pharmaceuticals shares in Q1 2024, an estimated $26.8K.
  • Fennec Pharmaceuticals made up 0.21% of Eudaimonia Advisors's portfolio in Q1 2024, its #118 holding.
  • Eudaimonia Advisors first reported a position in Fennec Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
  • 65 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2024.

Based on Eudaimonia Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.